Leading the IU Simon Cancer Center's efforts are George W. Sledge, Jr., MD, and Patrick J. Loehrer, Sr., MD. They will work closely with WellPoint's clinical experts, and with IU's trusted informatics partner, the Regenstrief Institute, to provide advice on how the solutions may be best utilized in clinical practice to support increased understanding of the evolving body of knowledge in cancer, including emerging therapies not widely known by community physicians. As the solutions are developed, Drs. Sledge and Loehrer will also provide guidance to WellPoint.
"As we design the WellPoint systems that leverage IBM Watson's capabilities, it is essential that we incorporate the highly-specialized knowledge and real-life practice experiences of the nation's premier clinical experts," said Harlan Levine, MD, executive vice president of WellPoint's Comprehensive Health Solutions. "The contributions from Dr. Sledge and Dr. Loehrer, coupled with the expertise throughout the IU Simon Cancer Center, will be invaluable to implementing this WellPoint offering and could ultimately benefit millions of Americans across the country."
"Researchers from the IU Simon Cancer Center are leading clinical investigators who have set standards of care for treatment of numerous malignancies, including germ cell tumors, breast and thoracic tumors," said Dr. Loehrer, director of the IU Simon Cancer Center and HH Gregg Professor of Oncology at the IU School of Medicine. "We will also be working closely w
|Contact: Michael Schug|
Indiana University School of Medicine